⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RYTM News
Rhythm Pharmaceuticals, Inc. Common Stock
Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
globenewswire.com
RYTM
Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity
globenewswire.com
RYTM
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm
prnewswire.com
RYTM
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
globenewswire.com
RYTM
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm
globenewswire.com
RYTM
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
globenewswire.com
RYTM
Form 8-K
sec.gov
RYTM
Form 8-K
sec.gov
RYTM
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
globenewswire.com
RYTM
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
globenewswire.com
RYTM